CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 84 enrolled
Drug / intervention
Stereotactic ablative body radiotherapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01578902
NCT01578902N/ACompleted
CompareCT.gov

Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer (pHART 3)

Sunnybrook Health Sciences Centre·interventional·Posted Apr 17, 2012·Updated Dec 17, 2020

In Brief

A clinical study evaluating Stereotactic ablative body radiotherapy for Prostate Cancer. Completed, enrolled 84 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (35 Gy / 5 fractions / 29 days) for the treatment of low-risk prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada
CollaboratorsCanadian Association of Radiation Oncology

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 17, 2012
Enrollment StartOct 1, 2006
Primary CompletionApr 1, 2008
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.2 years ago

Interventions

Stereotactic ablative body radiotherapyradiation

35Gy/5 fractions/29 days